American Journal of Ophthalmology
Volume 150, Issue 3 , Pages 315-324.e1 , September 2010

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2

  • Prema Abraham

      Affiliations

    • Black Hills Regional Eye Institute, Rapid City, South Dakota
    • Corresponding Author InformationInquiries to Prema Abraham, Black Hills Regional Eye Institute, 2800 Third Street, Rapid City, SD 57701
    • ,
  • Huibin Yue

      Affiliations

    • Genentech, Inc, South San Francisco, California
    • ,
  • Laura Wilson

      Affiliations

    • Genentech, Inc, South San Francisco, California

,Accepted 18 April 2010.

References 

  1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431
  2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444
  3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57 e5–65 e5
  4. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124(11):1532–1542
  5. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239–248
  6. Collaborative overview of randomised trials of antiplatelet therapy—I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (Antiplatelet Trialists' Collaboration). BMJ. 1994;308(6923):81–106
  7. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999;117(10):1329–1345
  8. Bressler NM TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP Report 2. Arch Ophthalmol. 2001;119(9):198–207
  9. Campbell AJ, Robertson MC, La Grow SJ, et al. Randomised controlled trial of prevention of falls in people aged > or =75 with severe visual impairment: the VIP trial. BMJ. 2005;331(7520):817
  10. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800–802
  11. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627–637
  12. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566–583

PII: S0002-9394(10)00267-9

doi: 10.1016/j.ajo.2010.04.011

American Journal of Ophthalmology
Volume 150, Issue 3 , Pages 315-324.e1 , September 2010

Article Tools

* Image Usage & Resolution